{"entity":{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","aka":[],"tldr":"Florida leukaemia doctor who led the phase 3 trial of CPX-351, the liposomal form of daunorubicin and cytarabine that lengthened survival for older people with secondary acute myeloid leukaemia.","summary":"Jeffrey Lancet chairs the malignant haematology department at Moffitt Cancer Center in Tampa. He was first author of the 2018 Journal of Clinical Oncology report of the phase 3 trial in which CPX-351, a liposomal fixed-ratio formulation of daunorubicin and cytarabine, improved overall survival compared with standard 7+3 induction in patients aged 60 to 75 with newly diagnosed secondary AML, the basis of the drug's approval.","asOf":"2026-09-18","links":[],"tags":["leukaemia","trialist"],"related":[],"cancers":["aml-secondary","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cpx-351-study-301-lancet-je-jco-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Moffitt Cancer Center","institutionId":"moffitt","specialisms":["Acute myeloid leukaemia","Secondary AML","Novel formulations of chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lancet%5BAuthor%5D"}],"papers":[]},"route":"/people/jeffrey-lancet/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/"}],"institution":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/"}],"paper":[{"id":"paper-cpx-351-study-301-lancet-je-jco-2018","kind":"paper","name":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","route":"/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/"}]}}